Ancillary testing in prostate cancer

From Libre Pathology
Revision as of 15:09, 1 November 2022 by Michael (talk | contribs)
Jump to navigation Jump to search

Ancillary testing in prostate cancer is evolving. Prostate cancer panel redirect here.

PARP inhibitors

  • Poly(ADP-ribose) polymerases (PARP) inhibitors, e.g. olaparib, target BRCA1/2 mutations.[1]

Molecular panel:

  • BRCA1
  • BRCA2
  • ATM
  • PALB2

See also

References

  1. ↑ Dziadkowiec KN, Gąsiorowska E, Nowak-Markwitz E, Jankowska A (December 2016). "PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting". Prz Menopauzalny 15 (4): 215–219. doi:10.5114/pm.2016.65667. PMC 5327624. PMID 28250726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5327624/.
Retrieved from "https://librepathology.org/w/index.php?title=Ancillary_testing_in_prostate_cancer&oldid=52196"